# Medical Oncology (gastrointestinal) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Babe Didrikson Zaharias (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML038-SYN
- Date: 2026-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Jun-Ho Albright-Nakamura, MD
- Calendar frame: modern shifted

- Requested by: Rosalind Vasquez-Thornbury, MD

## Reason for consultation

Suspected low rectal cancer in a 41-year-old professional golfer with three months of rectal bleeding, narrower stools, urgency and tenesmus, a firm ulcerated mass felt on the posterior wall of the lower rectum at about 5 cm, iron deficiency anemia (hemoglobin 11.0 g/dL, ferritin 9 ng/mL) and CEA 5.8 ng/mL. Colonoscopy with biopsy is booked this week. Please see her within two weeks, with colorectal surgery, to review the results with her and plan staging and treatment if cancer is found. **S**

## History

Ms. Didrikson Zaharias, 41, is seen at the request of Dr. Vasquez-Thornbury two weeks after she presented with three months of rectal bleeding, a change in bowel habit and a rectal mass. Since then she has had a colonoscopy with biopsy, rectal-protocol MRI, CT of the chest, abdomen and pelvis, and review at our colorectal tumor board. She still passes a little bright red blood most days, with urgency, and tires late in a round. She has pain during sex and spotting afterwards. She is fully active (ECOG 0), has a levonorgestrel IUD and is not planning a pregnancy. She was seen by the colorectal surgeon this morning. She asked whether she would need a colostomy and whether she could keep playing. **S**

## Examination

| System | Finding |
|---|---|
| General | Fit and composed; weight 62.6 kg; blood pressure 116/72, pulse 80; ECOG 0 |
| Abdomen | Soft, non-tender; no liver enlargement |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Rectal | Firm, ulcerated mass on the posterior and left wall, lower edge about 4 to 5 cm from the anal verge; normal sphincter tone |

BP 116/72 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 62.6 kg; BMI 22.2 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Vasquez-Thornbury's intake note and results. Colonoscopy: ulcerated mass on the posterior and left wall of the lower rectum, 4 to 9 cm from the anal verge, about half the circumference; the rest of the colon normal. Pathology: adenocarcinoma, moderately differentiated; loss of MSH2 and MSH6 on immunohistochemistry with MLH1 and PMS2 retained; microsatellite instability high. Rectal-protocol MRI: tumor extending 4 mm beyond the muscularis propria (cT3b), two irregular 7 mm mesorectal nodes (cN1), mesorectal fascia clear by 6 mm, no extramural venous invasion, lower edge about 1 cm above the anorectal junction, sphincters not involved. CT of the chest, abdomen and pelvis: no metastases. CEA 5.8 ng/mL at the first visit. Today: hemoglobin 11.1 g/dL, platelets 405, creatinine 0.76 mg/dL, ALT 17 and AST 20 U/L, glucose 90 mg/dL, TSH 1.9 mIU/L, free T4 1.2 ng/dL; urine pregnancy test negative. Hemoglobin: 11.1 g/dL (low); White cell count: 6.5 10*3/uL; Platelets: 405 10*3/uL (high); Creatinine: 0.76 mg/dL; eGFR (CKD-EPI 2021): 101 mL/min/1.73 m²; Glucose: 90 mg/dL; ALT: 17 U/L; AST: 20 U/L; TSH: 1.9 mIU/L; Free T4: 1.2 ng/dL; PHQ-9: 6; GAD-7: 7. All results are synthetic.

## Assessment

1. **Low rectal adenocarcinoma, mismatch repair deficient, cT3bN1M0 (stage IIIB)** (C20). Locally advanced adenocarcinoma of the low rectum with no distant spread. For a mismatch repair-proficient tumor at this level the standard would be total neoadjuvant therapy (chemoradiation and chemotherapy) followed by total mesorectal excision, and because the lower edge is only about 1 cm above the anorectal junction the operation would most likely be an abdominoperineal resection with a permanent colostomy. This tumor is mismatch repair deficient, which changes everything: in the dostarlimab trial every patient with this kind of tumor who completed six months of treatment had a clinical complete response, and in the larger follow-up study nearly all kept their rectum without radiation or surgery, with few regrowths. The NCCN and ASCO guidelines now recommend checkpoint inhibitor immunotherapy for mismatch repair-deficient locally advanced rectal cancer. The aim is cure with the rectum and sphincter preserved; radiation and surgery remain available if the response is incomplete or the tumor regrows. **S**
2. **Iron deficiency anemia from blood loss** (D50.0). From the tumor's bleeding; oral iron is enough while the bleeding settles with treatment. **S**

## Recommendations

1. Dostarlimab 500 mg intravenously every three weeks for nine doses (six months), starting next week.
2. Restaging with rectal-protocol MRI, flexible sigmoidoscopy and digital rectal examination after about three months and again after the last dose, with CT of the chest, abdomen and pelvis at the end; CEA at each restaging.
3. If there is a clinical complete response at the end of treatment, watch-and-wait: examination and sigmoidoscopy every three to four months and MRI every six months for two years, CEA every three to six months, CT every six to twelve months, and colonoscopy at one year.
4. If the response is incomplete, chemoradiation and total mesorectal excision, with stoma site marking and teaching by the wound-ostomy nurse before any operation; no stoma preparation is needed now.
5. Germline multigene panel after genetic counseling, because she is under 50 and the tumor is mismatch repair deficient; if negative, tumor sequencing for somatic MSH2 or MSH6 variants. Her first-degree relatives should start colonoscopy at 40, or 10 years before her age at diagnosis if earlier, every five years, with more intensive Lynch syndrome surveillance only if a germline variant is found.
6. Before the first dose: hepatitis B, hepatitis C and HIV screening, a pregnancy test, and baseline TSH, free T4, liver and kidney tests and glucose.
7. During treatment, primary care to watch for immune-related adverse events, the commonest being thyroid inflammation: TSH and free T4 every six weeks, liver and kidney tests and glucose before each dose, and same-day review for diarrhea, blood in the stool, rash, cough, breathlessness, headache, thirst or unusual tiredness.
8. Oral iron for the anemia, with a blood count in four weeks.
9. She can keep training and competing; dostarlimab does not limit exercise. Contraception with her IUD during treatment and for four months after the last dose; dostarlimab is not known to harm fertility. Sexual pain and spotting should settle as the tumor responds.
10. Distress screening at each visit; she decides who receives these notes.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Vasquez-Thornbury and presented at the colorectal tumor board with colorectal surgery, radiation oncology, radiology, pathology and genetics. The images, the biopsy and the meaning of mismatch repair deficiency were explained to Ms. Didrikson Zaharias in plain words, including that surgery would most likely mean a permanent colostomy and that immunotherapy offers a good chance of avoiding it. She chose dostarlimab with watch-and-wait if the response is complete. She decides who else receives this note. **S**

## Follow-up

Cycle 1 next week; oncology review before each dose; restaging after four doses and after nine; Dr. Vasquez-Thornbury continues primary care and shares the monitoring. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026), National Comprehensive Cancer Network
- Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 2024;42(28):3355-3375 (PMID 39116386) (2024), American Society of Clinical Oncology
- Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022), New England Journal of Medicine
- Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025), New England Journal of Medicine
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024), American Society of Clinical Oncology
- Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017), U.S. Multi-Society Task Force on Colorectal Cancer
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38(31):3698-3715 (PMID 32716741) (2020), American Society of Clinical Oncology
- Oktay K, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36(19):1994-2001 (PMID 29620997) (2018), American Society of Clinical Oncology
- Ligibel JA, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol 2022;40(22):2491-2507 (PMID 35576506) (2022), American Society of Clinical Oncology
